Please Wait...

Michael W. Weiner

Translation skills

Main profile

Michael W. Weiner, MD
Senior Scientific Advisor

Michael Weiner, MD, is a Professor in Residence in Radiology and Biomedical Engineering, Medicine, Psychiatry, and Neurology at the University of California, San Francisco.  He is Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and served as the Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center for nearly 10 years.

After graduating from the Johns Hopkins University in 1961, He obtained his MD from SUNY Upstate Medical Center in Syracuse, New York in 1965, and he completed his internship and residency in Medicine from Mt. Sinai Hospital in 1967.  From 1967-1968, Dr. Weiner completed a residency and clinical fellowship in Metabolism from Yale-New Haven Medical Center.  In 1970, he completed a research fellowship in Nephrology from Yale University School of Medicine and a research fellowship in Biochemistry from the University of Wisconsin Institute for Enzyme Research in 1972, followed by a joint appointment in the Department of Medicine; Renal Section from the University of Wisconsin Institute in 1972.  In 1974 he became an Assistant Professor of Medicine (Nephrology) at Stanford University, and in 1980 he became an Associate Professor of Medicine (Nephrology) at UCSF.  In 1983 he established the Magnetic Resonance Unit at the San Francisco VA Medical Center, which became the Center for Imaging of Neurodegenerative Diseases in 2004.  In 1990 he became a Professor of Radiology, Medicine, Psychiatry and Neurology at UCSF.

Dr. Weiner's research activities involve the development and utilization of MRI and PET for investigating and diagnosing neurodegenerative diseases.  In 1980, Dr. Weiner was one of the first to perform MRS on an intact animal, and subsequently pursued his goal to develop MRI/S as a clinical tool.  Over the past 25 years, he has worked to develop and optimize the use of MRI, PET, and blood based biomarker methods to diagnose Alzheimer's disease and other neurodegenerative disorders.

Dr. Weiner's research focuses on monitoring effects of treatment to slow progressions in Alzheimer's disease and the early detection of Alzheimer's disease in patients.  He has also launched The Brain Health Registry, which is a web-based registry for recruiting, screening, and longitudinally monitoring subjects for neuroscience studies of all types.  Dr. Weiner has over 650 published articles and has authored over 70 book chapters.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

In our latest blog post, we review the "burdens" of #CTMS implementation - and how better solutions address them.… https://t.co/vcyS2gvwpu
Bioclinica (2 days ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/01liAxqx0J
Bioclinica (3 days ago)
Rapid implementation. Increased control & efficiency. Out-of-the-box configuration. Turn-key validation. Cost savin… https://t.co/XO53jwd2DV
Bioclinica (2 weeks ago)
David Scott, PhD, Bioclinica Dir Medical & Science Affairs, will present on longitudinal progression of DaTscan bin… https://t.co/ZtxVWMlznP
Bioclinica (2 weeks ago)
Bioclinica's #IRT uses an agile delivery methodology, which means flexible configuration and customization, and del… https://t.co/SRd2uNscWc
Bioclinica (2 weeks ago)
Presenting Bioclinica CTMS: a rapid startup #CTMS that takes 2 weeks to implement, rather than months. Bioclinica C… https://t.co/9IH38ix6nW
Bioclinica (3 weeks ago)